Tags : P-I/IIa

Johnson & Johnson Initiates P-I/IIa Study of its Ad26.COV2.S Against

Shots: J&J’s Ad26 vector-based vaccine demonstrated robust immune response in the pre-clinical study by neutralizing Abs, preventing infection and provide complete/ near-complete protection in the lungs from the virus in NHPs Based on the preclinical studies, the company has commenced the P-I/IIa study of Ad26.COV2.S, in healthy volunteers in the US and Belgium with expected […]Read More

BioInvent Reports the Enrollment of First Patient in P-I/IIa Study

Shots: The focus of the study is to evaluate safety and tolerability profile of the combination of BI-1206 with Keytruda, characterizing PK/PD profile and to determine the recommended dose of the combination regimen The study is divided into two parts into Part A, a dose escalation of BI-1206 in combination with the standard dose of […]Read More

Johnson & Johnson to Initiate P-I/IIa Clinical Study of its

Shots: Janssen has accelerated the initiation of the P-I/IIa study of its investigational Ad26.COV2-S recombinant vaccine. Earlier, the company had scheduled the clinical trial to begin in Sept’2020, the trial is now expected to commence in the second half of July The P-I/IIa study will evaluate the safety, reactogenicity & immunogenicity Ad26.COV2-S, recombinant in 1045 […]Read More

BioInvent to Initiate P-I/IIa Study with BI-1206 in Combination with

Shots: In July’2019, Bioinvent reports the FDA’s acceptance of its IND application of BI-1206 + Keytruda combination therapy based on the preclinical data demonstrating that BI-1206 enhances anti-tumor immune responses in patients with solid tumors BioInvent will evaluate the combination therapy in P-I/IIa study in patients with an advanced solid tumor, prior treated with anti-PD1 […]Read More